Dopamine and α-synuclein dysfunction in Smad3 null mice

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Tapia González, Silvia ^a,c   Giráldez Pérez, Rosa M ^a,c   Cuartero, M Isabel ^a,c   Casarejos, M José ^a,c   Mena, M Ángeles ^a,c   Wang, Xiao Fan ^b   Sánchez Capelo, Amelia ^a,c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Astrocytes; Dopamine; MAO B; MAPK; Parkinson's disease; Smad3; Synucleinopathy; TGF ; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 3; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; MITOGEN ACTIVATED PROTEIN KINASE; SMAD3 PROTEIN, MOUSE; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CATABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; HOMEOSTASIS; HUMAN; MALE; MESENCEPHALON; MOUSE; NERVE CELL; NERVE CELL DEGENERATION; NEURITE; NONHUMAN; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SPINAL CORD; STRIATE CORTEX; ANIMAL; C57BL MOUSE; CYTOLOGY; DOPAMINERGIC NERVE CELL; GENETICS; METABOLISM; MOUSE MUTANT; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA;

MUS;

ALPHA-SYNUCLEIN; ANIMALS; DOPAMINE; DOPAMINERGIC NEURONS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SUBSTANTIA NIGRA; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN;

EID: 80053900398     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-72     Document Type: Article

References (63)

1. Roles for nigrostriatal - not just mesocorticolimbic - dopamine in reward and addiction. Wise RA, Trends Neurosci 2009 32 517 524 10.1016/j.tins.2009.06. 004 19758714
2. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Sulzer D, Trends Neurosci 2007 30 244 250 10.1016/j.tins.2007.03.009 17418429 (Pubitemid 46667168)
3. TGF-beta1 and TGF-beta2 expression after traumatic human spinal cord injury. Buss A, Pech K, Kakulas BA, Martin D, Schoenen J, Noth J, Brook GA, Spinal Cord 2008 46 364 371 10.1038/sj.sc.3102148 18040277 (Pubitemid 351630959)
4. Transforming growth factor-beta 1 (TGF-beta 1) in patients with amyotrophic lateral sclerosis. Ilzecka J, Stelmasiak Z, Dobosz B, Cytokine 2002 20 239 243 10.1006/cyto.2002.2005 12550109 (Pubitemid 37163477)
5. Increased expression of TGF-beta 1 in brain tissue after ischemic stroke in humans. Krupinski J, Kumar P, Kumar S, Kaluza J, Stroke 1996 27 852 857 10.1161/01.STR.27.5.852 8623105 (Pubitemid 26142515)
6. Expression of TGF-beta s and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus. Li XF, Miyajima M, Jiang CL, Arai H, Neurosci Lett 2007 413 141 144 10.1016/j.neulet.2006.11. 039 17194537 (Pubitemid 46195188)
7. Transforming growth factor-beta-1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T, Neurosci. Lett 1995 193 129 132 10.1016/0304-3940(95)11686-Q 7478158
8. Differential expression of TGF-beta-1, TGF-beta-2 and TGF-beta-3 isotypes in Alzheimer's disease-a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. Peress NS, Perillo E, J Neuropathol Exp Neurol 1995 54 802 811 10.1097/00005072-199511000-00007 7595653
9. Transforming Growth Factor-Beta-1 Is in Plaques in Alzheimer and Down Pathologies. van der Wal EA, Gámez-Pinilla F, Cotman CW, Neuroreport 1993 4 69 72 10.1097/00001756-199301000-00018 8453039 (Pubitemid 23066393)
10. TGF beta 1 and TGF beta 2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Vawter MP, Dillon-Carter O, Tourtellotte WW, Carvey P, Freed WJ, Exp. Neurol 1996 142 313 322 10.1006/exnr.1996.0200 8934562 (Pubitemid 26414063)
11. Dual role for TGF-beta 1 in apoptosis. Sánchez-Capelo A, Cytokine Growth Factor Rev 2005 16 15 34 10.1016/j.cytogfr.2004.11.002 15733830 (Pubitemid 40279115)
12. Transcriptional control of synaptic differentiation by retrograde signals. Kalinovsky A, Scheiffele P, Curr Opin Neurobiol 2004 14 272 279 10.1016/j.conb.2004.05.011 15194106 (Pubitemid 38759857)
13. Retrograde regulation in the CNS: Neuron-specific interpretations of TGF-beta signaling. Sanyal S, Kim SM, Ramaswami M, Neuron 2004 41 845 848 10.1016/S0896-6273(04)00152-7 15046717 (Pubitemid 38429728)
14. Role of transforming growth factor-beta in long-term synaptic facilitation in Aplysia. Zhang F, Endo S, Cleary LJ, Eskin A, Byrne JH, Science 1997 275 1318 1320 10.1126/science.275.5304.1318 9036859 (Pubitemid 27114162)
15. Essential function of HIPK2 in TGF beta-dependent survival of midbrain dopamine neurons. Zhang JS, Pho V, Bonasera SJ, Holtzman J, Tang AT, Hellmuth J, Tang SW, Janak PH, Tecott LH, Huang EJ, Nat Neurosci 2007 10 77 86 10.1038/nn1816 17159989 (Pubitemid 46026530)
16. Reduction of endogenous transforming growth factors beta prevents ontogenetic neuron death. Krieglstein K, Richter S, Farkas L, Schuster N, Dunker N, Oppenheim RW, Unsicker K, Nat Neurosci 2000 3 1085 1090 10.1038/80598 11036264
17. Transforming growth factor beta 1 overexpression in the nigrostriatal system increases the dopaminergic deficit of MPTP mice. Sánchez-Capelo A, Colin P, Guibert B, Biguet NF, Mallet J, Mol Cell Neurosci 2003 23 614 625 10.1016/S1044-7431(03)00081-2 12932441 (Pubitemid 36970222)
18. Adenovirus-mediated over-expression of TGF beta 1 in the striatum decreases dopaminergic cell survival in embryonic nigral grafts. Sánchez-Capelo A, Corti O, Mallet J, Neuroreport 1999 10 2169 2173 10.1097/00001756-199907130-00031 10424693 (Pubitemid 29394066)
19. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Datto MB, Frederick JP, Pan LH, Borton AJ, Zhuang Y, Wang XF, Mol Cell Biol 1999 19 2495 2504 10082515 (Pubitemid 29144493)
20. Apoptosis in Parkinson's disease: Signals for neuronal degradation. Tatton WG, Chalmers-Redman R, Brown D, Tatton N, Ann Neurol 2003 53 61 S70 10.1002/ana.10489 12666099 (Pubitemid 36368563)
21. Parkinson disease: A new link between monoamine oxidase and mitochondrial electron flow. Cohen G, Farooqui R, Kesler N, Proc Natl Acad Sci USA 1997 94 4890 4894 10.1073/pnas.94.10.4890 9144160 (Pubitemid 27214706)
22. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. Mallajosyula JK, Kaur D, Chinta SJ, Rajagopalan S, Rane A, Nicholls DG, Di Monte DA, Macarthur H, Andersen JK, PLOS One 2008 3 2 1616 10.1371/journal.pone.0001616 18286173 (Pubitemid 351863345)
23. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Damier P, Kastner A, Agid Y, Hirsch EC, Neurology 1996 46 1262 1269 8628464 (Pubitemid 26159284)
24. Specificity and versatility in TGF-beta signaling through Smads. Feng XH, Derynck R, Annu Rev Cell Dev Biol 2005 21 659 693 10.1146/annurev.cellbio.21. 022404.142018 16212511 (Pubitemid 41740650)
25. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P, Flavell RA, Proc Natl Acad Sci USA 2004 101 665 670 10.1073/pnas.0307453101 14704277 (Pubitemid 38084694)
26. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T, Am J Pathol 1998 152 879 884 9546347 (Pubitemid 28173348)
27. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Ihara M, Yamasaki N, Hagiwara A, Tanigaki A, Gitano A, Hikawa R, Tomimoto H, Noda M, Takanashi M, Mori H, Hattori N, Miyakawa T, Kinoshita M, Neuron 2007 53 519 533 10.1016/j.neuron.2007.01.019 17296554 (Pubitemid 46216751)
28. Chemokine expression in the white matter spinal cord precursor niche after force-defined spinal cord contusion injuries in adult rats. Knerlich-Lukoschus F, von der Ropp-Brenner B, Lucius R, Mehdorn HM, Held-Feindt J, Glia 2010 58 916 931 20155816
29. Role of post-translational modifications in modulating the structure, function and toxicity of -synuclein: implications for Parkinson's disease pathogenesis and therapies. Oueslati A, Fournier M, Lashuel HA, Progress in Brain Research Academic Press, Anders Björklund, M Angela Cenci, 183, chapter 7 115 145
30. Hierarchical model of gene regulation by transforming growth factor beta. Yang YC, Piek E, Zavadil J, Liang D, Xie D, Heyer J, Pavlidis P, Kucherlapati R, Roberts AB, Böttinger EP, Proc Natl Acad Sci USA 2003 100 10269 10274 10.1073/pnas.1834070100 12930890 (Pubitemid 37071868)
31. Non-Smad TGF-beta Signaling Pathways. Zhang YE, The TGF- Family New York: CSHLP, Derynck R, Miyazono K, 2007 419 437 22006998
32. Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Zhu JH, Guo FL, Shelburne J, Watkins S, Chu CT, Brain Pathol 2003 13 473 481 14655753 (Pubitemid 37420692)
33. Transforming growth factor-2 increases extracellular matrix proteins in optic nerve head cells via activation of the Smad signaling pathway. Zode GS, Sethi A, Brun-Zinkernagel AM, Chang IF, Clark AF, Wordinger RJ, Mol Vision 2011 17 1745 1758
34. Smad3-dependent signaling underlies the TGF-1-mediated enhancement in astrocytic iNOS expression. Hamby ME, Hewett JA, Hewett SJ, Glia 2010 58 1282 1291 20607716
35. TGFbeta1 induces Jagged1 expression in astrocytes via ALK5 and Smad3 and regulates the balance between oligodendrocyte progenitor proliferation and differentiation. Zhang Y, Zhang J, Navrazhina K, Argaw AT, Zameer A, Gurfein BT, Brosnan CF, John GR, Glia 2010 58 964 974 20169621
36. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. Rich JN, Zhang M, Datto MB, Bigner DD, Wang XF, Journal of Biologycal Chemistry 1999 274 35053 35058 10.1074/jbc.274.49.35053 (Pubitemid 129509557)
37. Astroglia in dementia and Alzheimer's disease. Rodriguez JJ, Olabarria M, Chvatal A, Verkhratsky A, Cell Death Diff 2009 16 378 385 10.1038/cdd.2008.172
38. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Zigmond MJ, Hastings TG, Perez RG, Parkinsonism Relat Disord 2002 8 389 393 10.1016/S1353-8020(02)00019-6 12217625 (Pubitemid 36151654)
39. Future directions in the treatment of Parkinson's disease. Schapira AH, Mov Disord 2007 Suppl 17 385 391
40. Gene dosage and pathogenesis of Parkinson's disease. Eriksen JL, Przedborski S, Petrucelli L, Trends Mol Med 2005 11 91 96 10.1016/j.molmed.2005. 01.001 15760766 (Pubitemid 40348985)
41. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C, Am J Pathol 2001 159 2215 2225 10.1016/S0002-9440(10)63072-6 11733371 (Pubitemid 33104275)
42. Alpha-synuclein in Lewy bodies. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M, Nature 1997 388 839 840 10.1038/42166 9278044 (Pubitemid 27377048)
43. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Burke WJ, Kumar V, Pandey N, Panneton WM, Gan Q, Franko MW, O'Dell M, Li SW, Pan Y, Chung HD, Galvin JE, Acta Neuropathol 2008 115 193 203 10.1007/s00401-007-0303-9 17965867
44. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms. Halliday GM, McCann H, Exp Neurol 2008 209 12 21 10.1016/j.expneurol.2007.07.006 17706644
45. Staging of brain pathology related to sporadic Parkinson's disease. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E, Neurobiol Aging 2003 24 197 211 10.1016/S0197-4580(02)00065-9 12498954 (Pubitemid 36007810)
46. Examining Braak's hypothesis by imaging Parkinson's disease. Brooks DJ, Mov Disord 2010 25 Suppl 1 83 88 20187242
47. Parkinsonism. Lang A, Cecil Medicine Philadelphia: Saunders Elsevier, Goldman L, Ausiello D, 23 2007 chap 433
48. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, Shen J, J Biol Chem 2003 278 43628 43635 10.1074/jbc.M308947200 12930822 (Pubitemid 37345989)
49. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, Ret G, Joubert C, Periquet M, Araujo F, Negroni J, Casarejos MJ, Canals S, Solano R, Serrano A, Gallego E, Sanchez M, Denefle P, Benavides J, Tremp G, Rooney TA, Brice A, Garcia de Yebenes J, Hum Mol Genet 2003 12 2277 91 10.1093/hmg/ddg239 12915482 (Pubitemid 37160872)
50. Parkin-deficient mice are not a robust model of parkinsonism. Perez FA, Palmiter RD, Proc Natl Acad Sci USA 2005 102 2174 2179 10.1073/pnas.0409598102 15684050 (Pubitemid 40262031)
51. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, Tong Y, Martella G, Tscherter A, Martins A, Bernardi G, Roth BL, Pothos EN, Calabresi P, Shen J, Neuron 2005 45 489 496 10.1016/j.neuron.2005.01.041 15721235 (Pubitemid 40249861)
52. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, Martella G, Bonsi P, Zhang C, Pothos EN, Shen J, Proc Natl Acad Sci USA 2007 104 11441 11446 10.1073/pnas.0702717104 17563363 (Pubitemid 47175159)
53. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Abeliovich A, Schmitz Y, Farĩas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A, Neuron 2000 25 239 252 10.1016/S0896-6273(00)80886-7 10707987 (Pubitemid 30316525)
54. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL, J Neurosci 2002 22 8797 8807 12388586 (Pubitemid 35379049)
55. Prime time for alpha-synuclein. Gitler AD, Shorter J, J Neurosci 2007 27 2433 2434 10.1523/JNEUROSCI.0094-07.2007 17344380 (Pubitemid 46393580)
56. Neuroanatomical phenotyping in the mouse: the dopaminergic system. Zeiss CJ, Vet Pathol 2005 42 753 773 10.1354/vp.42-6-753 16301571 (Pubitemid 41695359)
57. The mouse brain in stereotaxic coordinates, Compact. Paxinos G, Franklin K, London: Academic Press third 2007
58. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. West MJ, Slomianka L, Gundersen HJ, Anat Rec 1991 231 482 497 10.1002/ar.1092310411 1793176
59. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. German DC, Nelson EL, Liang CL, Speciale SG, Sinton CM, Sonsalla PK, Neurodegeneration 1996 5 299 312 10.1006/neur.1996.0041 9117541 (Pubitemid 27077888)
60. mRNA expression of type I and type II receptors for activin, transforming growth factor-beta, and bone morphogenetic protein in the murine erythroleukemic cell line, F5-5.fl. Machida H, Ogawa K, Funaba M, Mizutani T, Tsujimoto M, Eur J Endocrinol 2000 143 705 710 10.1530/eje.0.1430705 11078996
61. Effects of calcium antagonists on the dopamine system. Mena MA, Garcia de Yebenes MJ, Tabernero C, Casarejos MJ, Pardo B, Garcia de Yebenes J, Clin Neuropharmacol 1995 18 410 426 10.1097/00002826-199510000-00004 8665555
62. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: application to mammalian blood and other tissue. Tietze F, Anal Biochem 1969 27 502 522 10.1016/0003-2697(69)90064-5 4388022
63. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Griffith OW, Anal Biochem 1980 106 207 212 10.1016/0003-2697(80)90139-6 7416462 (Pubitemid 11246585)